Intravitreal Fluocinolone Acetonide Implant (ILUVIEN^®) for the Treatment of Retinal Conditions. A Review of Clinical Studies

References

• Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. Retina. 2009;29(7):875–912. doi:10.1097/IAE.0b013e3181a94f01
   PubMed Web of Science ®Google Scholar
• Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye. 2013;27(7):787–794. doi:10.1038/eye.2013.107
   PubMed Web of Science ®Google Scholar
• Massa H, Nagar AM, Vergados A, Dadoukis P, Patra S, Panos GD. Intravitreal fluocinolone acetonide implant (ILUVIEN(R)) for diabetic macular oedema: a literature review. J Int Med Res. 2019;47(1):31–43. doi:10.1177/0300060518816884
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Nguyen QD, Hafiz G, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120(3):583–587. doi:10.1016/j.ophtha.2012.09.014
   PubMed Web of Science ®Google Scholar
• Drugs.com. FDA approves iluvien; 2014. Available from: https://www.drugs.com/newdrugs/fda-approves-iluvien-diabetic-macular-edema-4092.html. Accessed March 23, 2023.
   Google Scholar
• Cadth.ca. Clinical review report: fluocinolone acetonide intravitreal implant (Iluvien): (Knight Therapeutics Inc.): indication: for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Ottawa (ON); 2019. Available from: https://www.cadth.ca/sites/default/files/cdr/relatedinfo/sr0608-iIluvien-clinical-review-report.pdf. Accessed March 28, 2023.
   Google Scholar
• Medicine and Healthcare products Regulatory Agency. Iluvien 190 micrograms intravitreal implant in applicator (fluocinolone acetonide): public assessment report; 2016.
   Google Scholar
• Alimera Sciences Inc. Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg for intravitreal injection: US prescribing information; 2014. Available from: http://www.fda.gov. Accessed March 23, 2023.
   Google Scholar
• Sarao V, Veritti D, Boscia F, Lanzetta P. Intravitreal steroids for the treatment of retinal diseases. ScientificWorldJournal. 2014;2014:989501. doi:10.1155/2014/989501
   PubMedGoogle Scholar
• Kang BS, Chung EY, Yun YP, et al. Inhibitory effects of anti-inflammatory drugs on interleukin-6 bioactivity. Biol Pharm Bull. 2001;24(6):701–703. doi:10.1248/bpb.24.701
   PubMed Web of Science ®Google Scholar
• Holmquist F, Lundin S, Larsson B, Hedlund H, Andersson KE. Studies on binding sites, contents, and effects of AVP in isolated bladder and urethra from rabbits and humans. Am J Physiol. 1991;261(4 Pt 2):R865–874. doi:10.1152/ajpregu.1991.261.4.R865
   PubMedGoogle Scholar
• Glybina IV, Kennedy A, Ashton P, Abrams GW, Iezzi R. Photoreceptor neuroprotection in RCS rats via low-dose intravitreal sustained-delivery of fluocinolone acetonide. Invest Ophthalmol Vis Sci. 2009;50(10):4847–4857. doi:10.1167/iovs.08-2831
   PubMed Web of Science ®Google Scholar
• Ayalasomayajula SP, Ashton P, Kompella UB. Fluocinolone inhibits VEGF expression via glucocorticoid receptor in human retinal pigment epithelial (ARPE-19) cells and TNF-alpha-induced angiogenesis in chick chorioallantoic membrane (CAM). J Ocul Pharmacol Ther. 2009;25(2):97–103. doi:10.1089/jop.2008.0090
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125–2132. doi:10.1016/j.ophtha.2012.04.030
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626–635 e622. doi:10.1016/j.ophtha.2010.12.028
   PubMed Web of Science ®Google Scholar
• Syed YY. Fluocinolone acetonide intravitreal implant 0.19 mg (ILUVIEN((R))): a review in diabetic macular edema. Drugs. 2017;77(5):575–583. doi:10.1007/s40265-017-0722-4
   PubMed Web of Science ®Google Scholar
• Glybina IV, Kennedy A, Ashton P, Abrams GW, Iezzi R. Intravitreous delivery of the corticosteroid fluocinolone acetonide attenuates retinal degeneration in S334ter-4 rats. Invest Ophthalmol Vis Sci. 2010;51(8):4243–4252. doi:10.1167/iovs.09-4492
   PubMed Web of Science ®Google Scholar
• Campochiaro PA. Pharmacokinetics of sustained-delivery fluocinolone acetonide for DMO. Retina Today. 2009;2009:55–56.
   Google Scholar
• Tan GS, Cheung N, Simo R, Cheung GC, Wong TY. Diabetic macular oedema. Lancet Diabetes Endocrinol. 2017;5(2):143–155. doi:10.1016/S2213-8587(16)30052-3
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995;102(1):7–16. doi:10.1016/S0161-6420(95)31052-4
   PubMed Web of Science ®Google Scholar
• Pacella F, Ferraresi AF, Turchetti P, et al. Intravitreal Injection of Ozurdex((R)) implant in patients with persistent diabetic macular edema, with six-month follow-up. Ophthalmol Eye Dis. 2016;8:11–16. doi:10.4137/OED.S38028
   PubMedGoogle Scholar
• Holden SE, Currie CJ, Owens DR. Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 microg intravitreal implant in people with diabetic macular edema. Curr Med Res Opin. 2017;33(sup2):5–17. doi:10.1080/03007995.2017.1366645
   PubMed Web of Science ®Google Scholar
• El-Ghrably I, Steel DHW, Habib M, Vaideanu-Collins D, Manvikar S, Hillier RJ. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 microg/d intravitreal implant: real-world UK experience. Eur J Ophthalmol. 2017;27(3):357–362. doi:10.5301/ejo.5000929
   PubMed Web of Science ®Google Scholar
• Fusi-Rubiano W, Mukherjee C, Lane M, et al. Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien) at 2 years. BMC Ophthalmol. 2018;18(1):62. doi:10.1186/s12886-018-0726-1
   PubMed Web of Science ®Google Scholar
• Bailey C, Chakravarthy U, Lotery A, Menon G, Talks J, Medisoft Audit G. Real-world experience with 0.2 mug/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Eye. 2017;31(12):1707–1715. doi:10.1038/eye.2017.125
   PubMed Web of Science ®Google Scholar
• Figueira J, Henriques J, Amaro M, Rosas V, Alves D, Cunha-Vaz J. A nonrandomized, open-label, multicenter, phase 4 pilot study on the effect and safety of ILUVIEN(R) in chronic diabetic macular edema patients considered insufficiently responsive to available therapies (RESPOND). Ophthalmic Res. 2017;57(3):166–172. doi:10.1159/000455235
   PubMed Web of Science ®Google Scholar
• Bertelmann T, Schulze S. Long-term follow-up of patient with diabetic macular edema receiving fluocinolone acetonide intravitreal implant. Ophthalmol Ther. 2015;4(1):51–58. doi:10.1007/s40123-015-0028-0
   PubMedGoogle Scholar
• Elaraoud I, Andreatta W, Kidess A, et al. Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting. BMC Ophthalmol. 2016;16:3. doi:10.1186/s12886-015-0178-9
   PubMed Web of Science ®Google Scholar
• Elaraoud I, Attawan A, Quhill F. Case series investigating the efficacy and safety of bilateral fluocinolone acetonide (ILUVIEN((R))) in patients with diabetic macular edema. Ophthalmol Ther. 2016;5(1):95–104. doi:10.1007/s40123-016-0045-7
   PubMed Web of Science ®Google Scholar
• Elaraoud I, Quhill H, Quhill F. Case series investigating the efficacy and safety of bilateral fluocinolone acetonide (ILUVIEN((R))) in patients with diabetic macular edema: 10 eyes with 12 months follow-up. Ophthalmol Ther. 2016;5(1):105–109. doi:10.1007/s40123-016-0049-3
   PubMed Web of Science ®Google Scholar
• Massin P, Erginay A, Dupas B, Couturier A, Tadayoni R. Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study. Clin Ophthalmol. 2016;10:1257–1264. doi:10.2147/OPTH.S105385
   PubMed Web of Science ®Google Scholar
• Currie CJ, Holden SE, Owens DR. Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 microg intravitreal implant for diabetic macular edema. Curr Med Res Opin. 2017;33(sup2):33–43. doi:10.1080/03007995.2017.1366662
   PubMed Web of Science ®Google Scholar
• Panos GD, Arruti N, Patra S. The long-term efficacy and safety of fluocinolone acetonide intravitreal implant 190 mug (ILUVIEN((R))) in diabetic macular oedema in a multi-ethnic inner-city population. Eur J Ophthalmol. 2021;31(2):620–629. doi:10.1177/1120672119898414
   PubMed Web of Science ®Google Scholar
• Singer MA, Sheth V, Mansour SE, Coughlin B, Gonzalez VH. Three-year safety and efficacy of the 0.19-mg fluocinolone acetonide intravitreal implant for diabetic macular edema: the PALADIN study. Ophthalmology. 2022;129(6):605–613. doi:10.1016/j.ophtha.2022.01.015
   PubMed Web of Science ®Google Scholar
• Uy HS, Yu-Keh E, Chan PS. Posterior Uveitis. Dev Ophthalmol. 2016;55:163–166.
   PubMedGoogle Scholar
• Massa H, Georgoudis P, Panos GD. Dexamethasone intravitreal implant (OZURDEX((R))) for macular edema secondary to noninfectious uveitis: a review of the literature. Ther Deliv. 2019;10(6):343–351. doi:10.4155/tde-2019-0024
   PubMed Web of Science ®Google Scholar
• Bodaghi B, Nguyen QD, Jaffe G, Khoramnia R, Pavesio C. Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye - evaluating the 0.2 mug/day fluocinolone acetonide intravitreal implant (ILUVIEN((R))). J Ophthalmic Inflamm Infect. 2020;10(1):32. doi:10.1186/s12348-020-00225-z
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Lin P, Keenan RT, Ashton P, Skalak C, Stinnett SS. Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: two-year results. Ophthalmology. 2016;123(9):1940–1948. doi:10.1016/j.ophtha.2016.05.025
   PubMed Web of Science ®Google Scholar
• Pavesio C, Heinz C. Non-infectious uveitis affecting the posterior segment treated with fluocinolone acetonide intravitreal implant: 3-year fellow eye analysis. Eye. 2022;36(6):1231–1237. doi:10.1038/s41433-021-01608-9
   PubMed Web of Science ®Google Scholar
• Weber LF, Marx S, Auffarth GU, et al. Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema. J Ophthalmic Inflamm Infect. 2019;9(1):3. doi:10.1186/s12348-019-0168-9
   PubMedGoogle Scholar
• Jaffe GJ, Pavesio CE, Study I. Effect of a fluocinolone acetonide insert on recurrence rates in noninfectious intermediate, posterior, or panuveitis: three-year results. Ophthalmology. 2020;127(10):1395–1404. doi:10.1016/j.ophtha.2020.04.001
   PubMed Web of Science ®Google Scholar
• Hikal M, Celik N, Auffarth GU, Kessler LJ, Mayer CS, Khoramnia R. Intravitreal 0.19 mg fluocinolone acetonide implant in non-infectious uveitis. J Clin Med. 2021;10(17):3966. doi:10.3390/jcm10173966
   PubMed Web of Science ®Google Scholar
• Pockar S, Leal I, Chhabra R, Jones NP, Steeples LR. Intravitreal fluocinolone 0.19mg implant in the management of chronic non-infectious uveitis: 12-month outcomes from a single tertiary centre. Ocul Immunol Inflamm. 2021;1–7:54.
   Google Scholar
• Battista M, Starace V, Cicinelli MV, et al. Efficacy of 0.19 mg fluocinolone acetonide implant in non-infectious posterior uveitis evaluated as area under the curve. Ophthalmol Ther. 2022;11(1):215–224. doi:10.1007/s40123-021-00426-2
   PubMed Web of Science ®Google Scholar
• Buhl L, Thurau S, Kern C. Fluocinolone acetonide 0.19-mg implant for the treatment of noninfectious uveitis with involvement of the posterior segment: a real-world study. Graefes Arch Clin Exp Ophthalmol. 2022. doi:10.1007/s00417-022-05893-2
   PubMed Web of Science ®Google Scholar
• Orskov M, Vorum H, Bjerregaard Larsen T, et al. A review of risk factors for retinal vein occlusions. Expert Rev Cardiovasc Ther. 2022;20(9):761–772. doi:10.1080/14779072.2022.2112667
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Sonoda KH, Sugahara M, et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One. 2009;4(12):e8158. doi:10.1371/journal.pone.0008158
   PubMed Web of Science ®Google Scholar
• Ford JA, Clar C, Lois N, et al. Treatments for macular oedema following central retinal vein occlusion: systematic review. BMJ Open. 2014;4(2):e004120. doi:10.1136/bmjopen-2013-004120
   PubMed Web of Science ®Google Scholar
• Coelho J, Pessoa B, Meireles A. Long-term management of non-ischemic central retinal vein occlusion with fluocinolone acetonide intravitreal implant 190 mug (ILUVIEN(R)). Ther Adv Ophthalmol. 2019;11:2515841418820755. doi:10.1177/2515841418820755
   Web of Science ®Google Scholar
• Ribeiro M, Pereira AF, Penas S, Falcão-Reis F, Beato JN. 12-Month Effectiveness of the Fluocinolone Acetonide Implant (ILUVIEN^®) in Retinal Vein Occlusions – Two Clinical Cases. EURETINA; 2021.
   Google Scholar
• Kessel L, Tendal B, Jorgensen KJ, et al. Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops: a systematic review. Ophthalmology. 2014;121(10):1915–1924. doi:10.1016/j.ophtha.2014.04.035
   PubMed Web of Science ®Google Scholar
• Miguel-Escuder L, Olate-Perez A, Sala-Puigdoners A, et al. Intravitreal fluocinolone acetonide implant for the treatment of persistent post-surgical cystoid macular edema in vitrectomized eyes. Eur J Ophthalmol. 2021;2021:11206721211046718.
   Google Scholar
• Chronopoulos A, Chronopoulos P, Hattenbach LO, et al. Intravitreal fluocinolone acetonide implant for chronic postoperative cystoid macular edema - two years results. Eur J Ophthalmol;2022;11206721221124688. doi:10.1177/11206721221124688
   Web of Science ®Google Scholar
• Alfaqawi F, Lip PL, Elsherbiny S, Chavan R, Mitra A, Mushtaq B. Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom. Eye. 2017;31(4):650–656. doi:10.1038/eye.2016.301
   PubMed Web of Science ®Google Scholar
• Ch’ng SW, Brent AJ, Empeslidis T, Konidaris V, Banerjee S. Real-world cost savings demonstrated by switching patients with refractory diabetic macular edema to intravitreal fluocinolone acetonide (Iluvien): a retrospective cost analysis study. Ophthalmol Ther. 2018;7(1):75–82. doi:10.1007/s40123-017-0114-6
   PubMed Web of Science ®Google Scholar
• Schmit-Eilenberger VK. A novel intravitreal fluocinolone acetonide implant (Iluvien((R))) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series. Clin Ophthalmol. 2015;9:801–811. doi:10.2147/OPTH.S79785
   PubMed Web of Science ®Google Scholar
• Currie CJ, Holden SE, Berni E, Owens DR. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 microg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. Curr Med Res Opin. 2017;33(sup2):19–31. doi:10.1080/03007995.2017.1366659
   PubMed Web of Science ®Google Scholar
• Meireles A, Goldsmith C, El-Ghrably I, et al. Efficacy of 0.2 mug/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy. Eye. 2017;31(5):684–690. doi:10.1038/eye.2016.303
   PubMed Web of Science ®Google Scholar
• Pessoa B, Coelho J, Correia N, Ferreira N, Beirao M, Meireles A. Fluocinolone acetonide intravitreal implant 190 mug (ILUVIEN(R)) in vitrectomized versus nonvitrectomized eyes for the treatment of chronic diabetic macular edema. Ophthalmic Res. 2018;59(2):68–75. doi:10.1159/000484091
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Taylor SR, Koch FHJ, Castro de Sousa JP, Bailey C. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries. Br J Ophthalmol. 2019;103(8):1072–1077. doi:10.1136/bjophthalmol-2018-312284
   PubMed Web of Science ®Google Scholar
• ILUVIEN. Summary of product characteristics. Available from: https://www.medicines.org.uk/emc/medicine/27636. Accessed March 23, 2023.
   Google Scholar
• Parrish RK, Campochiaro PA, Pearson PA, Green K, Traverso CE. Characterization of intraocular pressure increases and management strategies following treatment with fluocinolone acetonide intravitreal implants in the FAME trials. Ophthalmic Surg Lasers Imaging Retina. 2016;47(5):426–435. doi:10.3928/23258160-20160419-05
   PubMed Web of Science ®Google Scholar
• Yang Y, Bailey C, Holz FG, et al. Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants. Eye. 2015;29(9):1173–1180. doi:10.1038/eye.2015.98
   PubMed Web of Science ®Google Scholar
• Cunha-Vaz J, Ashton P, Iezzi R, et al. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology. 2014;121(10):1892–1903. doi:10.1016/j.ophtha.2014.04.019
   PubMed Web of Science ®Google Scholar
• Andreatta W, Elaraoud I, Mitra A. Dislodgement of fluocinolone acetonide intravitreal implant into the infusion cannula during vitrectomy for retinal detachment. Retin Cases Brief Rep. 2020;14(3):215–217. doi:10.1097/ICB.0000000000000678
   PubMedGoogle Scholar
• de Oliveira Dias JR, Nunes RP, Goldhardt R. New drugs and new posterior delivery methods in CME. Curr Ophthalmol Rep. 2017;5(2):160–168. doi:10.1007/s40135-017-0134-3
   PubMedGoogle Scholar
• Royal National Institute of Blind People (UK). Sight loss UK 2013. The latest evidence (2013); 2013. Available from: www.rnib.org.uk/sites/default/files/sight_loss_UK_2013.pdf. Accessed March 23, 2023.
   Google Scholar
• Quhill F, Beiderbeck A. Cost advantage of fluocinolone acetonide implant (ILUVIEN) versus ranibizumab in the treatment of chronic diabetic macular oedema. Glob Reg Health Technol Assess. 2017;3(2):25.
   Google Scholar
• Neubauer AS, Haritoglou C, Ulbig MW. Kostenvergleich zugelassener intravitrealer Therapien bei nicht ausreichend auf primäre Therapie ansprechendem diabetischem Makulaödem mit fovealer Beteiligung in Deutschland [Cost comparison of licensed intravitreal therapies for insufficiently anti-VEGF responding fovea involving diabetic macular edema in Germany]. Klin Monbl Augenheilkd. 2019;236(2):180–191. German. doi:10.1055/s-0043-125076
   PubMed Web of Science ®Google Scholar
• Sivaprasad S, Oyetunde S. Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol. 2016;10:939–946. doi:10.2147/OPTH.S100168
   PubMed Web of Science ®Google Scholar
• Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol. 2010;21(3):178–183. doi:10.1097/ICU.0b013e328338679a
   PubMed Web of Science ®Google Scholar